November 11, 2008
The Vanderbilt-Ingram Cancer Center Receives CEO Cancer Gold Standard(TM) Accreditation
The Vanderbilt-Ingram Cancer Center was accredited with the CEO Cancer Gold Standard(TM) certification, recognizing the organization's commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.
William C. Weldon, chairman and chief executive officer of Johnson & Johnson chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs that created the CEO Cancer Gold Standard(TM), in collaboration with the National Cancer Institute, many of its designated cancer centers, American Cancer Society, CDC and leading health professionals.
The CEO Cancer Gold Standard(TM), calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.
The most recent President's Cancer Panel report, "Maximizing our Nation's Investment in Cancer: Three Crucial Actions for America's Health", identified the CEO Cancer Gold Standard as an initiative that emphasizes cancer screening, tobacco control, cancer education, lifestyle modification, and access to cancer treatment when needed.
Vanderbilt-Ingram becomes the fourth NCI-designated cancer center to achieve Gold Standard accreditation, joining with the NCI, who also achieved Gold Standard accreditation earlier this year. Other organizations who are championing this workplace-based effort to eliminate cancer as a public health threat include: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, Duke Medicine, Edelman, Enzon Pharmaceuticals, GHI, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute (NCI), Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Quintiles Transnational, SAS Institute, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, Virtua Health and The Wistar Institute.
About the Vanderbilt-Ingram Cancer Center
The Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center is dedicated to a comprehensive, interdisciplinary approach to cancer care, research, prevention, and outreach. With nearly 300 investigators, Vanderbilt-Ingram is ranked among the top 10 centers in total National Cancer Institute funding and generates more than $150 million in total annual research support. Vanderbilt-Ingram is the only NCI-designated Comprehensive Cancer Center in Tennessee that conducts research and provides care for adult and pediatric cancers. The center is a member of the National Comprehensive Cancer Network and is consistently recognized among the best places for cancer care by U.S. News & World Report. For more information, visit www.vicc.org.
About the CEO Roundtable on Cancer
The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded with the CEO Cancer Gold Standard encouraging its widespread adoption in workplaces across the country. For more information on the CEO Cancer Gold Standard(TM) and the accreditation process, please visit www.CancerGoldStandard.org.
To read the President's Cancer Panel 2007- 2008 Report, please go to: